Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.46 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.44 |
| ▸ | RAD52 | P43351 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 5/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15796463 | 1.00 | NAAA (0.52) | NAAAEPHX1TSHRSPHK1HCAR2 | |
| SCHEMBL27733410 | 1.00 | NAAA (0.52) | NAAAEPHX1TSHRSPHK1HCAR2 | |
| SCHEMBL462188 | 1.00 | NAAA (0.52) | NAAAEPHX1TSHRSPHK1HCAR2 | |
| SCHEMBL15305328 | 1.00 | NAAA (0.52) | NAAAEPHX1TSHRSPHK1HCAR2 | |
| SCHEMBL21184186 | 1.00 | NAAA (0.52) | NAAAEPHX1TSHRSPHK1HCAR2 | |
| SCHEMBL15796319 | 1.00 | NAAA (0.52) | NAAAEPHX1TSHRSPHK1HCAR2 | |
| SCHEMBL453610 | 1.00 | NAAA (0.52) | NAAAEPHX1TSHRSPHK1HCAR2 | |
| SCHEMBL15305326 | 1.00 | NAAA (0.52) | NAAAEPHX1TSHRSPHK1HCAR2 | |
| SCHEMBL15796587 | 1.00 | NAAA (0.52) | NAAAEPHX1TSHRSPHK1HCAR2 | |
| Hydrochloric Acid SCHEMBL15568552 | 0.98 | NAAA (0.50) | NAAAEPHX1TSHRSPHK1HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4338740-A1 | A TRANSDERMAL PATCH FOR PROMOTING OR ACCELERATING MYELINATION AND/OR REMYELINATION | Johannes Gutenberg-Universität Mainz (DE) | 2024-03-20 | — | — | EP | claimed |
| US-11872319-B2 | Intraoperative topically-applied non-implantable rapid release patch | PRIVO TECHNOLOGIES, INC. (US) | 2024-01-16 | — | — | US | claimed |
| EP-4168116-A1 | TOPICAL FORMULATIONS OF (1S)-1-PHENYL-2-PYRIDIN-2-YLETHANAMINE | Biohaven Therapeutics Ltd. (US) | 2023-04-26 | — | — | EP | claimed |
| CN-115836052-A | Topical formulations of (1S) -1-phenyl-2-pyridin-2-ylethylamine | 拜尔哈文制药股份有限公司 | 2023-03-21 | — | — | CN | claimed |
| US-11357792-B2 | Method of administration and treatment | Dyvve Biosciences, Inc. (US) | 2022-06-14 | — | — | US | claimed |
| CN-114404424-A | A pharmaceutical composition for treating alopecia, and its preparation method | 硬核医药科技(上海)有限公司 | 2022-04-29 | — | — | CN | claimed |
| US-11246932-B2 | Prostaglandin compositions and methods for the treatment of vasospasm | NEXMED HOLDINGS, INC. (US) | 2022-02-15 | — | — | US | claimed |
| WO-2021262779-A1 | TOPICAL FORMULATIONS OF (1S)-1-PHENYL-2-PYRIDIN-2-YLETHANAMINE | BIOHAVEN THERAPEUTICS LTD. (US) | 2021-12-30 | — | — | WO | claimed |
| EP-3820452-A1 | STABILIZED FORMULATIONS OF CANNABINOID COMPOSITIONS | Berl, Volker (US) | 2021-05-19 | — | — | EP | claimed |
| US-20210093646-A1 | TOPICAL COMPOSITIONS COMPRISING BIMATOPROST AND METHODS FOR STIMULATING HAIR GROWTH THEREWITH | ALLERGAN INC (US) | 2021-04-01 | — | — | US | claimed |
| EP-1178833-A1 | TOPICAL COMPOSITIONS FOR PROSTAGLANDIN E 1? DELIVERY | Nexmed Holdings, Inc. (US) | 2002-02-13 | — | — | EP | claimed |
| US-6323241-B1 | PLACING IN THE FOSSA NAVICULARIS PROSATGLANDIN E1 AND A SKIN PENETRATION ENHANCER OF AMINOALKYLESTERS, GUM, LIPOPHILIC COMPOUND AND ACID BUFFER | NEXMED (HOLDINGS) INC. | 2001-11-27 | — | — | US | claimed |
| WO-2001074279-A1 | TOPICAL COMPOSITIONS CONTAINING PROSTAGLANDIN E¿1? | NEXMED HOLDINGS, INC. (US) | 2001-10-11 | — | — | WO | claimed |
| WO-2001051053-A1 | PROSTAGLANDIN COMPOSITIONS AND METHODS OF TREATMENT FOR MALE ERECTILE DYSFUNCTION | NEXMED HOLDINGS, INC. (US) | 2001-07-19 | — | — | WO | claimed |
| EP-1097126-A1 | CRYSTALLINE SALTS OF DODECYL 2-(N,N-DIMETHYLAMINO)-PROPIONATE | Nexmed Holdings, Inc. (US) | 2001-05-09 | — | — | EP | claimed |
| WO-2000069469-A1 | TOPICAL COMPOSITIONS FOR PROSTAGLANDIN E1 DELIVERY | NEXMED HOLDINGS, INC. (US) | 2000-11-23 | — | — | WO | claimed |
| WO-2000069809-A1 | CRYSTALLINE SALTS OF DODECYL 2-(N,N-DIMETHYLAMINO)-PROPIONATE | NEXMED HOLDINGS, INC. (US) | 2000-11-23 | — | — | WO | claimed |
| US-6118020-A | SALT FORMATION, PRECIPITATION, TRANSDERMAL DRUG DELIVERY PENETRATION AGENT | NEXMED HOLDINGS, INC. (US) | 2000-09-12 | — | — | US | claimed |
| US-6046244-A | COMPOSITION COMPRISING PROSTAGLANDIN E1, SKIN PENETRATION ENHANCER, POLYSACCHARIDE GUM, LIPOPHILIC COMPOUND, ACIDIC BUFFER SYSTEM | NEXMED HOLDINGS, INC. (US) | 2000-04-04 | — | — | US | claimed |
| US-5861431-A | Incontinence treatment | IOTEK, INC. (US) | 1999-01-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210093646-A1 | TOPICAL COMPOSITIONS COMPRISING BIMATOPROST AND METHODS FOR STIMULATING HAIR GROWTH THEREWITH | FGF1, CYP21A2, HDGF | NAAA 1678/4885EPHX1 1503/4885TSHR 494/4885 |
| US-11246932-B2 | Prostaglandin compositions and methods for the treatment of vasospasm | PTGIS, PTGIR, PGF | NAAA 2123/4885EPHX1 447/4885TSHR 2900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.